Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Sep 21, 2021 1:51pm
81 Views
Post# 33892964

RE:RE:RE:RE:Further to my TNSH listing idea

RE:RE:RE:RE:Further to my TNSH listing ideaWhy wouldn't they if it gives them a nice little profit from where the convert is currently trading. There is nothing special about TH's convert - it can be easily replaced with others in any convertible portfolio. Now, I would not expect all the convert holders to convert since many are likely held in none institutional hands. But for those that are held in institutional hands they may well take you up on the offer. 

palinc2000 wrote: Why would  holders of the Convert tender ?? A tender Offer at par would be ignored by the Holders 

SPCEO1 wrote: That is correct. But what I am talking about is a tender offer for those converts.
palinc2000 wrote: I am pretty sure that the Convert cannot be redeemed before maturity except if the SP close to maturity exceeds or is equal to the Conversion price

 




<< Previous
Bullboard Posts
Next >>